Human USP18 protects diverse cancer lineages from Type I Interferon independently of its canonical catalytic function
Preprint
Abstract
Precise temporal regulation of Type I interferon signaling is imperative to effectively fight infections and cancerous cells without triggering autoimmunity. The key negative regulator of Type I interferon signaling is ubiquitin-specific protease 18 (USP18). USP18 cleaves interferon-inducible ubiquitin-like modifications through its canonical catalytic function and directly inhibits interferon receptor signaling through its scaffold role. USP18 loss-of-function dramatically impacts autoimmune disease, viral susceptibility, and cancer cell survival. However, the relative contribution of catalytic versus scaffold function is unresolved and must be determined to design effective therapeutics targeting USP18. To precisely delineate individual contribution, we evaluated the functional impact of single amino acid mutations that disrupt catalytic or scaffold activity. Here we demonstrate catalytic activity does not contribute to cell autonomous Type I interferon sensitivity across multiple cancer cell lineages. Furthermore, introducing a patient-derived mutation that disrupts scaffold function is sufficient to inhibit cancer growth. These findings establish a fundamental mechanistic basis for USP18 therapeutic design across diseases. OVERVIEW: USP18 is the key negative regulator of Type I interferon signaling in humans, mediating autoimmune disease, viral susceptibility, and cancer cell survival. USP18 cleaves interferon-inducible ubiquitin-like modifications through its canonical catalytic function and attenuates interferon receptor signaling through its scaffold role. Delineating the contribution of each function is critical to resolve the mechanistic basis of interferon regulation and enable the development of therapeutics targeting USP18. We demonstrate that cell intrinsic interferon sensitivity is not mediated by loss of catalytic activity. However, disruption of scaffold function by a patient-specific mutation inhibits cancer cell growth. Furthermore, we discovered that canonical catalytic activity is surprisingly inefficient in human cells. These results clarify a fundamental mechanism of immune regulation and cancer cell survival in humans. Abstract Figure:Keywords
This publication has 59 references indexed in Scilit:
- Defense genes missing from the flight divisionDevelopmental & Comparative Immunology, 2013
- Activation of Double-stranded RNA-activated Protein Kinase (PKR) by Interferon-stimulated Gene 15 (ISG15) Modification Down-regulates Protein TranslationJournal of Biological Chemistry, 2013
- USP18-Based Negative Feedback Control Is Induced by Type I and Type III Interferons and Specifically Inactivates Interferon α ResponsePLOS ONE, 2011
- The ISG15 Conjugation System Broadly Targets Newly Synthesized Proteins: Implications for the Antiviral Function of ISG15Molecular Cell, 2010
- Antiproliferative Properties of Type I and Type II InterferonPharmaceuticals, 2010
- ISG15 conjugation system targets the viral NS1 protein in influenza A virus–infected cellsProceedings of the National Academy of Sciences, 2010
- ISG15 Arg151 and the ISG15-Conjugating Enzyme UbE1L Are Important for Innate Immune Control of Sindbis VirusJournal of Virology, 2009
- Mice Lacking the ISG15 E1 Enzyme UbE1L Demonstrate Increased Susceptibility to both Mouse-Adapted and Non-Mouse-Adapted Influenza B Virus InfectionJournal of Virology, 2009
- An investigation into the minimum requirements for peptide hydrolysis by mutation of the catalytic triad of trypsinJournal of the American Chemical Society, 1992
- The Three-Dimensional Structure of Asn 102 Mutant of Trypsin: Role of Asp 102 in Serine Protease CatalysisScience, 1987